SCHEMBL25480261

SCHEMBL25480261

CC(C)C1CN(CC2CCN(C(C)C)CC2)C1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 10/20 0.36
ACHE P22303 1/20 0.32
CHRM5 P08912 1/20 0.32
ADRA2C P18825 1/20 0.32
OPRM1 P35372 1/20 0.32
OPRD1 P41143 1/20 0.32
OPRK1 P41145 1/20 0.32
OPRL1 P41146 1/20 0.32
KCNH2 Q12809 2/20 0.32
SCN1A P35498 1/20 0.32
SCN4A P35499 1/20 0.32
SCN7A Q01118 1/20 0.32
SCN5A Q14524 1/20 0.32
SCN9A Q15858 1/20 0.32
SCN2A Q99250 1/20 0.32
SCN3A Q9NY46 1/20 0.32
SCN11A Q9UI33 1/20 0.32
SCN8A Q9UQD0 1/20 0.32
SCN10A Q9Y5Y9 1/20 0.32
TLR9 Q9NR96 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24833165 0.91 OPRL1 (0.37) HRH3OPRM1OPRD1OPRK1OPRL1
SCHEMBL26494310 0.89 HRH3 (0.35) HRH3ACHECHRM5ADRA2CTLR9
SCHEMBL22318585 0.89 HRH3 (0.35) HRH3ACHECHRM5ADRA2CTLR9
SCHEMBL26494311 0.89 HRH3 (0.35) HRH3ACHECHRM5ADRA2CTLR9
SCHEMBL24233175 0.85 ACHE (0.40) HRH3ACHECHRM5ADRA2CTLR9
SCHEMBL24843742 0.84 SCN1A (0.42) ACHECHRM5ADRA2COPRM1OPRD1
SCHEMBL25466871 0.83 ACHE (0.41) HRH3ACHECHRM5ADRA2COPRK1
SCHEMBL27051339 0.82
SCHEMBL25480296 0.82 HRH3 (0.35) HRH3ACHECHRM5ADRA2CKCNH2
SCHEMBL22520769 0.82 CHRM5 (0.43) HRH3ACHECHRM5ADRA2CKCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240024488-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2024-01-25 US disclosed
US-20240024488-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2024-01-25 US disclosed
WO-2023220137-A1 PYRAZINE DERIVATIVES AND USES THEREOF FOGHORN THERAPEUTICS INC. (US) 2023-11-16 WO disclosed
US-20230158151-A1 COMPOUNDS FOR INHIBITING OR DEGRADING TARGET PROTEINS, COMPOSITIONS, COMPRISING THE SAME, METHODS OF THEIR MAKING, AND METHODS OF THEIR USE NURIX THERAPEUTICS, INC. 2023-05-25 US disclosed
US-20230158151-A1 COMPOUNDS FOR INHIBITING OR DEGRADING TARGET PROTEINS, COMPOSITIONS, COMPRISING THE SAME, METHODS OF THEIR MAKING, AND METHODS OF THEIR USE NURIX THERAPEUTICS, INC. 2023-05-25 US disclosed
US-20230135894-A1 MK2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-05-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230135894-A1 MK2 DEGRADERS AND USES THEREOF MKNK2, MKRN3, DUS2 HRH3 3763/4885ACHE 1732/4885CHRM5 3811/4885
US-20240024488-A1 COMPOUNDS AND USES THEREOF VHL, CLN6, TFEB HRH3 3347/4885ACHE 4721/4885CHRM5 4760/4885
US-20230158151-A1 COMPOUNDS FOR INHIBITING OR DEGRADING TARGET PROTEINS, COMPOSITIONS, COMPRISING THE SAME, METHODS OF THEIR MAKING, AND METHODS OF THEIR USE MDM2, XIAP, ADRM1 HRH3 3926/4885ACHE 2289/4885CHRM5 4674/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.